Overview


According to FutureWise analysis the market for toxoplasmosis treatment in 2023 is US$ 0.75 billion, and is expected to reach US$ 1.11 billion by 2031 at a CAGR of 5.00%.

Toxoplasmosis, a zoonotic disease caused by the parasite toxoplasma bendy in humans, can cause a variety of clinical syndromes. Toxoplasmosis can be life-threatening, severe, and even fatal. Toxoplasmosis has been classified by the Centers for Disease Control and Prevention as one of five neglected parasitic infections. Although toxoplasmosis can affect many people, only a few may be affected by serious complications. Most patients experience flu-like symptoms until the parasite can be controlled by their immune system. However, the organism can be reactivated by people with compromised immunity. Active infection can also cause blindness, encephalitis, or other complications such as brain inflammation and death.

Toxoplasma gondii is a single-celled parasite that causes toxins. It can be found in cat feces as well as undercooked meats, such as lamb, venison, and pork. It can also be transmitted by unpasteurized goat milk and contaminated water. Rare cases of transmission from mother to child and during organ transplantation are possible. Blood tests are used to diagnose toxoplasmosis. Two types of antibodies can be detected by laboratory tests. The first antibody is an immune agent that is present in the body during active parasite infection. If you have had an infection in the past, another antibody may be present. Your healthcare provider might repeat the test after two weeks depending on the results. Depending on your symptoms and health, more diagnostic tests may be used.

Toxoplasmosis can cause flu-like symptoms, such as body aches and pains that can last up to a month. Toxoplasmosis may cause serious brain, eye, or other organ damage. Patients with compromised immune systems, HIV-positive/AIDS patients, chemotherapy patients, and pregnant women are more at risk for toxoplasmosis. There are four types: acute toxoplasmosis (CNS), congenital toxoplasmosis, and congenital toxoplasmosis. Acute toxoplasmosis can be symptomless and causes mild flu-like symptoms like fever and myalgia. CNS toxoplasmosis is a common infection in patients with AIDS and other immunocompromised patients. Congenital toxoplasmosis can be an asymptomatic condition that a mother may have contracted during pregnancy. Reactivated congenital diseases can cause ocular toxoplasmosis, which causes blurred vision and sometimes blindness. Toxoplasmosis is diagnosed by serological testing, CT and MRI scans as well as lumbar puncture, biopsy, and PCR. CNS toxoplasmosis is diagnosed by MRI and CT scans. Contrast agents and laboratory tests are also available. Toxoplasmosis patients are given pyrimethamine or sulphadiazine. Pregnant women who have been infected by the disease are given spiramycin, pyrimethamine, or sulphadiazine.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Toxoplasmosis Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Toxoplasmosis Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Amneal Pharmaceuticals Inc
  • Greenstone LLC
  • Vyera Pharmaceuticals LLC
  • Baxter International Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Turing Pharmaceuticals
  • Cerovene Healthcare Pvt Ltd.
  • Glaxo SmithKline
  • Taj Pharmaceuticals Ltd.
  • Hoffmann-la Roche AG

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product Type

  • Injection
  • Tablet
  • Others

By Application

  • Chronic Toxoplasmosis
  • Acute Toxoplasmosis
  • Congenital Toxoplasmosis

By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Drug Stores

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Toxoplasmosis Treatment Market By Product Type, By Application, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Toxoplasmosis Treatment Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Toxoplasmosis Treatment Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Toxoplasmosis Treatment Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Toxoplasmosis Treatment Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Injection
        2. Tablet
        3. Others

  • 8.   Toxoplasmosis Treatment Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Chronic Toxoplasmosis
        2. Acute Toxoplasmosis
        3. Congenital Toxoplasmosis

  • 9.   Toxoplasmosis Treatment Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Online Pharmacy
        3. Retail Pharmacy
        4. Drug Stores

  • 10.   North America Toxoplasmosis Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Toxoplasmosis Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Toxoplasmosis Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Toxoplasmosis Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Amneal Pharmaceuticals Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Greenstone LLC
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Vyera Pharmaceuticals LLC
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Baxter International Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Teva Pharmaceutical Industries Ltd.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Turing Pharmaceuticals
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Cerovene Healthcare Pvt Ltd.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Glaxo SmithKline
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Taj Pharmaceuticals Ltd.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Hoffmann-la Roche AG
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients